SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Terence A. Ketter, Shefali Miller, Bernardo Dell’Osso, Po W. Wang, Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium, Journal of Affective Disorders, 2016, 191, 256

    CrossRef

  2. 2
    Marta Fernández-Nogales, Félix Hernández, Andrés Miguez, Jordi Alberch, Silvia Ginés, Esther Pérez-Navarro, José J. Lucas, Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease, Human Molecular Genetics, 2015, 24, 17, 5040

    CrossRef

  3. 3
    Alberto Bocchetta, Raffaella Ardau, Tiziana Fanni, Claudia Sardu, Doloretta Piras, Antonello Pani, Maria Del Zompo, Renal function during long-term lithium treatment: a cross-sectional and longitudinal study, BMC Medicine, 2015, 13, 1, 12

    CrossRef

  4. 4
    A. Okada, Acute renal failure induced by markedly decreased appetite secondary to a depressive episode after discontinuation of long-term lithium therapy in an elderly patient with bipolar disorder, Case Reports, 2014, 2014, may15 1, bcr2013203422

    CrossRef

  5. 5
    Gin S. Malhi, Claire McAulay, Kristina Fritz, Current Status of Lithium in the Treatment of Mood Disorders, Current Treatment Options in Psychiatry, 2014, 1, 3, 294

    CrossRef

  6. 6
    R D Beech, J J Leffert, A Lin, L G Sylvia, S Umlauf, S Mane, H Zhao, C Bowden, J R Calabrese, E S Friedman, T A Ketter, D V Iosifescu, N A Reilly-Harrington, M Ostacher, M E Thase, A Nierenberg, Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS), The Pharmacogenomics Journal, 2014, 14, 2, 182

    CrossRef

  7. 7
    Anne Duffy, Interventions for Youth at Risk of Bipolar Disorder, Current Treatment Options in Psychiatry, 2014, 1, 1, 37

    CrossRef

  8. 8
    Dario Braga, Lucia Maini, Fabrizia Grepioni, Mechanochemical preparation of co-crystals, Chemical Society Reviews, 2013, 42, 18, 7638

    CrossRef

  9. 9
    Carol Paton, Roma Adroer, Thomas RE Barnes, Monitoring lithium therapy: the impact of a quality improvement programme in the UK, Bipolar Disorders, 2013, 15, 8
  10. 10
    Alessio Squassina, Claudia Pisanu, Personalized medicine in bipolar disorder: how can we overcome the barriers to clinical translation?, Personalized Medicine, 2013, 10, 8, 765

    CrossRef

  11. 11
    Willem A Nolen, Richard H Weisler, The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144), Bipolar Disorders, 2013, 15, 1
  12. 12
    Christine Vries, Annet Bergen, Eline J Regeer, Elsje Benthem, Ralph W Kupka, Marco PM Boks, The effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation-induced refractoriness, Bipolar Disorders, 2013, 15, 6
  13. 13
    Robert M. Post, Acquired lithium resistance revisited: Discontinuation-induced refractoriness versus tolerance, Journal of Affective Disorders, 2012, 140, 1, 6

    CrossRef

  14. 14
    Dario Braga, Fabrizia Grepioni, Lucia Maini, Davide Capucci, Saverio Nanna, Johan Wouters, Luc Aerts, Luc Quéré, Combining piracetam and lithium salts: ionic co-crystals and co-drugs?, Chemical Communications, 2012, 48, 66, 8219

    CrossRef

  15. 15
    Johanna Catalán, María Quezada, Lithium: Molecular interactions, clinical actions, Translational Neuroscience, 2012, 3, 1

    CrossRef

  16. 16
    B. Müller-Oerlinghausen, Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Kontra, Der Nervenarzt, 2012, 83, 9, 1191

    CrossRef

  17. 17
    H. Grunze, Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Pro, Der Nervenarzt, 2012, 83, 9, 1190

    CrossRef

  18. 18
    Gin S Malhi, Michelle Tanious, Samuel Gershon, The lithiumeter: a measured approach, Bipolar Disorders, 2011, 13, 3
  19. 19
    Robert M. Post, Susan R.B. Weiss, Tolerance to the Prophylactic Effects of Carbamazepine and Related Mood Stabilizers in the Treatment of Bipolar Disorders, CNS Neuroscience & Therapeutics, 2011, 17, 6
  20. 20
    Rif S. El-Mallakh, Yonglin Gao, A worldwide yearly survey of new data in adverse drug reactions, 2011,

    CrossRef

  21. 21
    Robert M Post, Letter to the editor regarding “A critical appraisal of lithium’s efficacy and effectiveness: the last 60 years”, Bipolar Disorders, 2010, 12, 4
  22. 22
    Raquel Gómez-Sintes, José J. Lucas, NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy, Journal of Clinical Investigation, 2010, 120, 7, 2432

    CrossRef

  23. 23
    Paul Grof, Bruno Müller-Oerlinghausen, Reply to Dr. Post, Bipolar Disorders, 2010, 12, 4
  24. 24
    Gin S Malhi, The king is dead, long live the king! The restoration of BALANCE, Bipolar Disorders, 2010, 12, 7
  25. 25
    Peter P. Zandi, Jennifer T. Judy, The Promise and Reality of Pharmacogenetics in Psychiatry, Psychiatric Clinics of North America, 2010, 33, 1, 181

    CrossRef

  26. 26
    Peter P. Zandi, Jennifer T. Judy, The Promise and Reality of Pharmacogenetics in Psychiatry, Clinics in Laboratory Medicine, 2010, 30, 4, 931

    CrossRef

  27. 27
    Samuel Gershon, KN Roy Chengappa, Gin S Malhi, Lithium specificity in bipolar illness: a classic agent for the classic disorder, Bipolar Disorders, 2009, 11,
  28. 28
    Gin S. Malhi, The impact of lithium on bipolar disorder, Bipolar Disorders, 2009, 11,